API /Small Molecule Manufacturing 

Current Trends in active pharmaceutical ingredients (API) show increasing offshoring activities and simultaneous advances in product and technology. We can help you deal with both. 

The synthesis of chemicals substance still accounts for the bulk of active pharmaceuticals ingredients. The major blockbuster ingredients are produced by well established processes, and many of the patents for these products have either expired or will expire in the next few years. This is leading to increased price pressure, an increasing share of generic products and increased focus on cost effective manufacturing.  

 In Industrialized countries, this has led to a decline in the number of API facilities. But in developing countries, particularly in Asia, the growth has been significant due to the transfer of production, and to the increasing consumption of pharmaceuticals. Besides the massive capacity investments, the boom in the Asian Pharma industry presents challenges such as technology transfer, auditing of suppliers and GMP compliance. 

At Integrated Project Services (IPS), we can offer expertise within a number of relevant processes, including synthesis and extraction processes. We also provide specialized knowledge of local conditions and the kind of technology transfer that is necessary for cost-effective global API bulk manufacturing.